All In Biotech

Drug Trial Radar · NCT07614477

Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases

The Sub-Study 3 of A Phase 1b/2 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases (ES108001)

Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

May 20, 2026

Primary completion

Dec 31, 2028

Study completion Mar 31, 2029

Sponsor

Sponsor type
Industry
First posted
May 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b/2, open-label, multi-center study evaluating the therapeutic potential and safety of the investigational drug EVER001 in adults with FSGS, MCD, or IgAN. EVER001 acts on multiple immune pathways without directly affecting T cells or depleting B cells (both are lymphocytes). The study will be conducted at \~30 centers in China, enrolling 45 participants aged 18-75 years (15 per indication). The IMP is a 100 mg oral capsule, dosed at 200 mg twice daily (2 capsules per dose, 4 daily) for 52 weeks.

Conditions

  • Minimal Change Disease (MCD)
  • IgA Nephropathy (IgAN)
  • Focal Segmental Glomerulosclerosis (FSGS)

Interventions

  • EVER001Drug

    EVER001 200 mg, oral administration, twice daily (bid), for the treatment of proteinuric glomerular diseases including FSGS , MCD , and IgA

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change from baseline in 24-hour urine protein-to-creatinine ratio (UPCR)Time frame: Week24
  2. Treatment-emergent adverse events (TEAEs)Time frame: Throughout the study period, up to Week 56
  3. Adverse events of special interest (AESIs)Time frame: Throughout the study period, up to Week 56
  4. Systolic blood pressure change from baselineTime frame: Throughout the study period, up to Week 56
  5. Body weight change from baselineTime frame: Throughout the study period, up to Week 56
  6. Change from baseline in clinical laboratory safety parametersTime frame: Throughout the study period, up to Week 56
  7. Physical examination findingsTime frame: Throughout the study period, up to Week 56
  8. Chest radiography findingsTime frame: Throughout the study period, up to Week 56
  9. 12-lead electrocardiogram (ECG) findingsTime frame: Throughout the study period, up to Week 56
  10. Pulse rate change from baselineTime frame: Throughout the study period, up to Week 56
  11. Diastolic blood pressure change from baselineTime frame: Throughout the study period, up to Week 56
  12. Body temperature change from baselineTime frame: Throughout the study period, up to Week 56

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Tianjin Medical University General Hospital

    Tianjin, Hebei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.